

## Press Release

**Matthias Link**  
Corporate Communications

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2872  
F +49 6172 608-2294  
matthias.link@fresenius.com  
www.fresenius.com

August 27, 2015

### **Fresenius expects 2015 dividend increase of more than 20%, will reach mid-term Group net income target ahead of schedule**

Fresenius expects a significant 2015 dividend increase, resulting from the forecasted 2015 net income growth applied to the company's dividend policy. After raising guidance twice this year, Fresenius is forecasting 2015 net income growth of 18% to 21% in constant currency. In addition, the company expects a significant positive currency effect. 2015 dividend growth is therefore expected to clearly exceed 20%. This will mark the company's 23rd consecutive year of dividend increases.

Ulf Mark Schneider, CEO of Fresenius, said: "Fresenius' business model is non-cyclical and we confirm our guidance for 2015. Our expectations for 2016 are also very positive, even in light of current concerns about the global economy."

In February 2014, Fresenius announced a net income target of €1.4 to €1.5 billion for 2017. Assuming stable exchange rates from here, Fresenius will reach that target this year – two years ahead of schedule. Even if the currency contribution declines in the coming months, the company will come very close.

"We therefore plan to provide a new mid-term target in February 2016 to guide investors' expectations regarding the company's future growth ambitions," Schneider said.

Fresenius will announce its Q3 2015 results on October 29, 2015.

# # #

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2014, Group sales were €23.2 billion. On June 30, 2015, the Fresenius Group had 220,339 employees worldwide.

For more information visit the Company's website at [www.fresenius.com](http://www.fresenius.com).

Follow us on Facebook and Twitter: [www.facebook.com/fresenius.group](https://www.facebook.com/fresenius.group) and <http://www.twitter.com/fresenius>.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg, HRB 11852  
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg, HRB 11673  
Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz,  
Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler  
Chairman of the Supervisory Board: Dr. Gerd Krick